Building 3D lab models from patient blood to study B-cell blood cancers
Uses extra blood from adults with CLL, splenic marginal zone lymphoma or hairy cell leukemia.
Key facts
- Who runs it
- IRCCS San Raffaele
- Where
- Milan, ItalySee the site
- Trial code
- Registry title
- Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies
- Status
- Not yet recruiting
- People taking part
- 64 people, planned
- Started
- Nov 2026
- Expected to end
- Nov 2029
- Type of study
- Observational, 3 groups
- Record updated
- 13 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic lymphocytic leukemia (CLL), splenic marginal zone lymphoma (SMZL) or hairy cell leukemia (HCL). A little extra blood is taken during routine blood draws.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Diagnosis of CLL, SMZL or HCL. No stage is named.
Main reasons for not taking part
- People who are unable or unwilling to give informed consent cannot join.
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Age ≥18 years
- Diagnosis of CLL, SMZL or HCL
- Participant is willing and able to autonomously give informed consent for participation in the study
Who cannot take part
- Participant is unable or unwilling to provide informed consent for participation in the study
Where in Italy
- IRCCS Ospedale San RaffaeleMilan, ItalyContact: Cristina Scielzo, PhDNo longer taking part
About the trial
What the trial wants to find out
Adult patients with chronic lymphocytic leukemia (CLL), splenic marginal-zone lymphoma (SMZL) and hairy cell leukemia (HCL) followed at participating clinical sites will be enrolled and undergo sampling of additional amount of blood during the blood draws performed as part of standard clinical care.
Read full original descriptionShow less
The project aims to develop and validate innovative patient-derived 3D bioprinted models that faithfully reproduce the key microenvironments of lymphoid tissues, enabling a more physiologically relevant study of mature B-cell malignancies.
The 3 groups in the trial
- CLL
Patients diagnosed with CLL
- SMZL
Patients diagnosed with SMZL
- HCL
Patients diagnosed with HCL
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies
- Plain-language title
- Building 3D lab models from patient blood to study B-cell blood cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 13 August 2026